Lisinopril

Generic Name: Lisinopril

Brand Names: Prinivil, Qbrelis, Zestoretic, Zestril

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₁N_₃O_₅

CAS Number: 76547-98-3

Unique Ingredient Identifier: 7Q3P4BS2FD

Background: Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.

Lisinopril was granted FDA approval on 29 December 1987.

Indication: Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.

Associated Conditions: Acute Myocardial Infarction (AMI), Cardiovascular Events, Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Migraine

Clinical Trials

Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations

Phase 1

Conditions: Healthy

Interventions: Drug: BF-Lisinopril Tablets 20mg
Drug: Zestril Tab 20mg

First Posted Date: 2018-07-26

Last Posted Date: 2019-01-16

Lead Sponsor: Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Target Recruit Count: 30

Registration Number: NCT03599466

N-of-1 Trials In Children With Hypertension

Phase 4

Completed

Conditions: Pediatric Hypertension

Interventions: Other: Usual care
Other: NICHE method
Drug: Amlodipine
Drug: Lisinopril
Drug: Hydrochlorothiazide
Drug: Losartan

First Posted Date: 2018-03-09

Last Posted Date: 2022-09-09

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 49

Registration Number: NCT03461003

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation

Phase 2

Not yet recruiting

Conditions: Pacemakers, Heart Failure

Interventions: Device: Optimised programming
Other: Standard care
Drug: Lisinopril

First Posted Date: 2018-02-06

Last Posted Date: 2022-11-02

Lead Sponsor: University of Leeds

Target Recruit Count: 75

Registration Number: NCT03422705

Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

Phase 4

Withdrawn

Conditions: Cardiomyopathy Due to Drug
Heart Failure, Systolic

Interventions: Drug: Placebo Oral Tablet
Drug: Lisinopril

First Posted Date: 2018-01-08

Last Posted Date: 2024-05-20

Lead Sponsor: Ascension Health

Registration Number: NCT03392740

Locations: 🇺🇸
Genesys Regional Medical Center, Grand Blanc, Michigan, United States

Optimal Management of HIV Infected Adults At Risk for Kidney Complications in Nigeria

Phase 2

Suspended

Conditions: HIV/AIDS
Kidney Diseases
Albuminuria
Genetic Predisposition

Interventions: Drug: Lisinopril
Other: Placebo Oral Tablet

First Posted Date: 2017-06-28

Last Posted Date: 2024-12-13

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 280

Registration Number: NCT03201939

Locations: 🇳🇬
Aminu Kano Teaching Hospital, Kano, Nigeria

Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)

Phase 4

Conditions: Renal Insufficiency, Chronic
Proteinuria

Interventions: Drug: Lisinopril
Drug: Amlodipine

First Posted Date: 2017-06-22

Last Posted Date: 2019-02-22

Lead Sponsor: Hospital General Universitario Gregorio Marañon

Target Recruit Count: 106

Registration Number: NCT03195023

Locations: 🇪🇸
Gregorio Maranon Hospital, Madrid, Spain

Comparison of Optimal Hypertension Regimens

Phase 4

Conditions: Hypertension

Interventions: Drug: Amlodipine
Drug: Lisinopril
Drug: Amiloride
Drug: Chlortalidone

First Posted Date: 2016-07-28

Last Posted Date: 2021-07-28

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 1320

Registration Number: NCT02847338

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
🇬🇧
University Hospital Llandough, Cardiff, United Kingdom
🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom

and more 11 locations

The Precision Hypertension Care Study

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Zestril®
Drug: Atacand®
Drug: Placebo
Drug: Norvasc®
Drug: Hydrochlorthiazide®
Drug: Treatment X
Drug: Treatment Y

First Posted Date: 2016-05-17

Last Posted Date: 2021-09-01

Lead Sponsor: Uppsala University

Target Recruit Count: 280

Registration Number: NCT02774460

Locations: 🇸🇪
Uppsala University hospital, Internal medicine research, Oscar II, Uppsala, Sweden

ACE-inhibitors in Extracapillary Glomerulonephritis

Phase 2

Conditions: Extracapillary Glomerulonephritis

Interventions: Drug: Lisinopril

First Posted Date: 2016-02-15

Last Posted Date: 2018-04-06

Lead Sponsor: Monia Lorini

Target Recruit Count: 22

Registration Number: NCT02682459

Locations: 🇮🇹
ASST Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica, Bergamo, Italy

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ITCA 650 20/60 mcg/day
Drug: Acetaminophen
Drug: Atorvastatin
Drug: Lisinopril
Drug: Warfarin
Drug: Digoxin

First Posted Date: 2015-12-30

Last Posted Date: 2017-01-27

Lead Sponsor: Intarcia Therapeutics

Target Recruit Count: 33

Registration Number: NCT02641899

Locations: 🇺🇸
Quintiles, Overland Park, Kansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy